 Ostia sarcoma is a type of bone cancer that is resistant to many treatments. A recent study has identified a gene called FUBP1 as a possible cause of this resistance. This gene can increase the production of prostaglandin e-synthase, PTGES, which then activates the arachidonic acid, AA, a metabolic pathway, leading to increased resistance to certain drugs such as loboplatin. By targeting FUBP1, PTGES, and the AA metabolic pathway, researchers have found a way to make ostia sarcoma cells more sensitive to loboplatin, potentially providing a new strategy for treating this difficult-to-treat form of cancer. This article was authored by Cheongma, Jinsun, Wanwang, and others.